This inventor holds 1 USPTO granted patent. Top assignee: Aventis Pharma Deutschland, Gmbh. Active years: 2003.
Company Filing History:
Years Active: 2003
Title: Claude Fudali: Innovator in Organic Chemistry
Introduction
Claude Fudali is an accomplished inventor based in Senlis, France. With a focus on organic chemistry, he has made significant contributions to the field through his innovative work. He is best known for obtaining a patent that details a unique process for synthesizing L-dihydroorotic acid.
Latest Patents
Fudali's notable patent, titled "Process for obtaining L-dihydroorotic acid and use thereof," encompasses a detailed methodology for generating L-dihydroorotic acid through chromatography on an anionic exchange material. This process is conducted in a base water mixture and operates under pressures ranging from about 1.1 MPa to approximately 40 MPa. The implications of this innovation extend to the investigation of the in vitro and in vivo activities of various compounds, including N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide and N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrontonamide.
Career Highlights
Claude Fudali is affiliated with Aventis Pharma Deutschland GmbH, where he applies his expertise in organic chemistry and contributes to pharmaceutical research and development. His career at this reputable company has positioned him among leading innovators in the field.
Collaborations
During his professional journey, Fudali has collaborated with esteemed coworkers such as Ulrike Milbert and Robert R. Bartlett. These collaborations reflect a commitment to advancing research initiatives and further developing innovative solutions in the pharmaceutical domain.
Conclusion
In conclusion, Claude Fudali stands out as a pivotal figure in organic chemistry, with a significant patent that enhances our understanding of L-dihydroorotic acid and its applications. His contributions through research at Aventis Pharma Deutschland GmbH and collaborative efforts underline his dedication to innovation in the pharmaceutical sector.
